2019 Executive Sponsors
2019 Associate Sponsors
2019 Technology Sponsors
2018 Executive Sponsors
2018 Associate Sponsors
2018 Technology Sponsors
2018 Supporting Sponsor
2018 Soapbox Sponsors
2018 Media Partners
2018 Conference Supporter
2018 Executive Sponsors
3M Drug Delivery Systems is a global leader and innovator for inhalation and transdermal drug delivery. Between drug discovery and commercialization, we offer: Innovative and proven technology; Global regulatory expertise; Commercial manufacturing; Broad range of customizable system components and product development services. Our expertise increases your opportunity for success. www.3m.com/dds.
BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD designs, manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. BD Medical – Pharmaceutical Systems is the partner of choice for the pharmaceutical industry. With innovative pre-fillable syringes, self-injection systems, safety systems and needle technologies, we offer an extensive selection of solutions designed to protect, package and deliver drug therapies. Our products reflect more than a century of experience and market knowledge, and our experts provide comprehensive system-based service and full product solutions. For more information, visit us at www.bd.com.
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business. With one of the largest, most robust pipelines in the industry — including more than 120 research projects and product candidates — we comprise nearly half of AstraZeneca’s overall R&D portfolio. MedImmune is pioneering innovative research and exploring novel pathways across Oncology; Respiratory, Cardiovascular & Metabolic Diseases; and Infection and Vaccines. Learn more at www.medimmune.com.
Phillips-Medisize, LLC, a Molex company, is a leading global outsource provider of design and manufacturing services to the drug delivery, consumable diagnostics, medical device, and specialty commercial markets. Backed by the combined global resources of Molex and its parent company Koch Industries, Phillips-Medisize’
2018 Associate Sponsors
Battelle combines medical device design and development, formulation expertise and human centric design to create innovative drug delivery systems that condense the development timeline and get our clients’ drugs to market faster. Battelle’s cross-disciplinary teams of experts mitigate risk and cut a clear path to regulatory approval for pharmaceutical companies looking to gain a competitive edge. Learn more at www.battelle.org.
Catalent is the #1 industry partner for advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise and the broadest portfolio of advanced technologies to bring more customer products to market faster, enhance product performance and ensure reliable clinical and commercial product supply. Our team of over 10,000 people, located at over 30 sites on five continents, produces +70 billion doses of +7,000 products for more than 1,000 customers. Our passion is to help unlock the full potential of your product.
Flex is the Sketch-to-Scale™ solutions provider that designs and builds Intelligent Products for a Connected World™. Flex Digital Health is partnering with pharmaceutical and medical technology companies to optimize real-world drug, device and combination products through real-time, integrated data and actionable insights. BrightInsight, a Flex Digital Health Solution, is a medical-grade IoT platform designed to support CE-marked and FDA-regulated medical devices, accelerate the time to market for our customers, and reduce the cost of implementation and maintenance. Learn more at www.flex.com.
Halozyme focuses on developing and commercializing novel enzymatic technologies that target the tumor microenvironment for treatment of cancer and facilitate drug delivery. Our proprietary ENHANZE™ drug delivery technology supports strong, value-driving partnerships with leading pharmaceutical companies including Roche, Shire, Pfizer, Janssen, AbbVie, Lilly, BMS, and Alexion. The ENHANZE™ platform has sales in 50+ countries through three product approvals. For more information, visit www.halozyme.com.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. Learn more at www.pfizer.com.
PharmaCircle is a trusted resource and full service solution delivering authoritative content, global insight, and expert analysis on the pharmaceutical, biotechnology, medical device and animal health industries. With in-depth coverage of research, development, regulatory, clinical, and commercial activities, PharmaCircle provides the information and analytics needed to answer challenging questions so you can uncover new opportunities and make informed decisions. Visit us at www.pharmacircle.com.
2018 Technology Sponsors
4P Therapeutics is focused on the research and development of novel drug delivery technologies and therapeutics. The name 4P recognizes the company’s mission to develop Products that meet the needs of Patients, Physicians and Payers (the 4 P’s). A key company focus and area of expertise is the development of transdermal products for currently injected compounds, including proteins, peptides, macromolecules and biologics. Transdermal delivery has the potential to improve the safety, efficacy and the therapeutic outcomes associated with these treatments. 4P was recently acquired by Nutriband, Inc. (OTC: NTRB), a results driven, health and pharmaceutical company. Learn more at www.4ptherapeutics.com.
Adare Pharmaceutical Technologies is seeking co-development partners who share our vision to improve the lives of patients whose treatment needs are not fully addressed by current medications. We have successfully transformed oral drug formulations and created differentiated patient-centric products. We add valuable IP to commercialized products and products in development. Learn more at www.adarepharma.com.
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Adocia recently expanded its portfolio to include the development of treatments of obesity and short bowel syndrome. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application. For more information, visit www.adocia.com.
Altaviz is an ISO 13485 medical device design and manufacturing organization with an experienced team of engineers with end-to-end product development capabilities. We have developed patented high performance drug delivery technology capable of injecting large volume high viscosity formulations through small gauge needles in 5 seconds or less. Learn more at www.altaviz.com.
Aquestive Therapeutics is a specialty pharmaceutical company that advances medicines to solve critical therapeutic problems and meaningfully improve people’s lives. We apply innovative drug delivery technology and scientific expertise to reinvent important medicines. Industry partners can leverage our versatile PharmFilm® platform to enhance existing molecules and optimize treatments for patients. Learn more at www.aquestive.com.
BDD is a specialist drug formulation company providing expertise in drug delivery. We offer a full service package to fit individual needs from troubleshooting, formulation development, in vitro and in vivo testing. Our patented time release technology OralogiK provides unrivalled control of drug release at the right place and time. Learn more at www.bddpharma.com.
Bespak, a Consort Medical company, is a global leader in the development and manufacture of complex drug delivery devices, including our innovative VapourSoft-powered Syrina injectable devices, our Unidose Xtra nasal drug delivery device, as well as best-in-class respiratory systems. Bespak’s expertise and capabilities have contributed to the industrialisation of some of the world’s leading medical devices. Bespak’s sister company Aesica is a leading pharmaceutical contract development and manufacturing organisation (CDMO) for both APIs and finished dosage forms. Working with our Aesica colleagues, we can now offer the design, development, manufacture, final assembly and packaging of filled single use devices, and in particular auto injectors and nasal devices. We have the experience and expertise to partner with pharmaceutical customers for seamless technology transfer at any stage to help bring their products to market quicker. Learn more at www.bespak.com.
For 20 years, BIOCORP has been developing and producing medical devices for the pharmaceutical industry, enhancing drug reconstitution, packaging and delivery. Recognized for its expertise in device R&D, BIOCORP has incorporated software development capacities to offer connected drug delivery systems in order to meet the evolving needs of patients and improve treatment adherence. Learn more at www.biocorp.fr.
Cambridge Design Partnership is an independent innovation and product development consultancy with offices in Cambridge, UK and Palo Alto, USA. Over the last 20 years, some of the world’s largest companies have trusted us with their most important product development programmes. We provide an integrated and holistic product development capability through our highly qualified team, well equipped development labs and ISO 13485/9001 approved methods. This encompasses research and strategy; design, technology and digital innovation; product development and manufacturing support including short run manufacture. Learn more about us at www.cambridge-design.co.uk.
Common Sensing develops and manufactures data-driven hardware and software solutions for people using injectable medicine. They’ve assembled a team of talented designers and engineers to develop Gocap™, the most advanced insulin adherence tool on the market. With Gocap patients, pharmacists and providers can make insulin therapy safer, more efficient, and more effective than ever. Learn more at www.common-sensing.com.
Our company’s mission is to develop and provide innovative drug delivery device solutions in congruence with unmet and under-served needs in ophthalmology. We are an innovation-centric company focused on the development and supply of leverage-able, fully customizable platforms, and on making available innovative products streamlined with standard pharmaceutical fill-finish infrastructure. For more information please visit: www.congruencemed.com.
Credence MedSystems is an innovator in injectable drug delivery devices, offering our pharma partners a simplified path to commercialization of a best-in-class delivery system. The Companion Safety Syringe System was born from Credence’s philosophy of Innovation Without Change, allowing our customers to impress and protect their end users while preserving their existing processes, sourcing strategies and preferred primary package components. The Companion is available in luer needle, staked needle and dual chamber reconstitution configurations. Across the platform, the user performs the injection, receives end-of-dose cues and then the needle automatically retracts into the syringe, preventing reuse. Visit us at www.credencemed.com.
Cureport leads the world in nanomedicine development with nPort, a revolutionary breakthrough in liposome technology. nPort’s unparalleled advantages include precise particle size control from 20 to 200 nm, robust reproducibility and homogeneity, flexible scalability, and a platform for all types of liposomes and payloads. It enables Cureport to quickly establish nanomedicine pipelines. Cureport welcomes investment and business partners for product co-development and comarketing. Learn more at www.cureportinc.com.
Daré Bioscience, Inc (“Daré”) is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health. We believe there is an unmet need globally for new product candidates that expand options, improve outcomes and are easy to use. By advancing these products, we seek to expand choices and to make a difference in the lives of women worldwide. For more information, please visit: www.
Datwyler Sealing Solutions is a leading industrial supplier and a key player in the global health care world. Our state-of-the-art solutions for drug packaging and medical devices, build on over 100 years of experience. Within our health care offering and its three pillars Bio Care, Pharma Care and Med Care, we provide a unique range of products and services including the most advanced elastomer formulations, coatings, aluminum seals, and processing technologies. Partnering up with the world’s top pharmaceutical and medical companies, we are a vital link and stand by our mission to ensure all patient’s safety and improve patients’ lives. Learn more at www.datwyler.com.
DelSiTech is an innovative, private drug delivery and drug development company based in Turku, Finland. DelSiTech works with its partners to transform their active agents into novel and commercially viable therapeutic drug products. The Company’s advanced proprietary technology, Silica Matrix, is a biodegradable and biocompatible extended/controlled release platform for parenteral administration of injectable depot and implant dosage forms, and topical delivery of eye drops. Silica Matrix is applicable to the formulation and delivery of small molecules, peptides, proteins, complex carbohydrates, RNA and even viruses and vaccines; it also offers thermostability and abuse deterrent properties. The technology can be used in an unlimited number of indications including oncology, metabolic disorders, infectious disease, gene therapy and ocular disease. In the case of ophthalmology, the Company is developing sustained release (6 months or more) intravitreal formulations and topical eye drops. DelSiTech also develops its own internal pipeline of supergeneric/505(b)(2) products. The Company’s lead product is 1308, a 3 month subcutaneous depot for hepatitis B. 1308 will enter the clinic in Q1 2019. Learn more at www.delsitech.com.
Enable Injections has developed a disposable on-body injector to deliver high volume, high viscosity drug/biological products (up to 50ml) subcutaneously. The system utilizes standard container closures (syringes or vials) and can automatically mix solutions or solubilize lyophilized product. The company is in Cincinnati Ohio. Visit us at enableinjections.com.
Evonik Industries, a global leader in specialty chemicals, provides drug delivery technologies, API manufacturing, intermediates, ingredients for nutraceuticals, amino acids and derivatives. Drug delivery technologies include formulation development services, solubility enhancement, functional excipients, bioresorbable polymers, lipid nanoparticles and GMP manufacturing for oral and parenteral formulations. Advanced delivery technologies for extended-release parenterals are offered for small molecules, peptides, proteins, antibodies, and nucleic acids. Learn more about us at www.evonik.com/healthcare.
Exicure, Inc is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Our proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure’s lead programs address oncology, inflammatory diseases and genetic disorders. We are based outside of Chicago, IL. Learn more at www.exicuretx.com.
Gerresheimer Medical Systems produces prefillable syringes and cartridges (primary packaging) made of glass and plastics worldwide, as well as customized drug delivery systems, diagnostics and medical products. Our full service includes industrial design, product and process development, engineering, industrialization, mold making, automation engineering, high volume production, product refinement, assembly, and packaging. Learn more at www.gerresheimer.com.
Harro Höfliger Verpackungsmaschinen GmbH is a globally acting technology leader for engineered production solutions in the pharmaceutics and medical sectors. The family run company with over 1,200 employees is internationally recognized for its customer-oriented process solutions and turnkey competence from lab to production. Learn more at www.hoefliger.com.
Ichor’s TriGrid® Delivery System is the first integrated and fully automated device for electroporation-mediated nucleic acid administration in humans. The TriGrid technology has been licensed by companies such as Pfizer and Janssen for delivery of nucleic acid-based vaccines. Ichor has also received funding from DARPA for nucleic acid-based antibody delivery. Ichor continues to seek strategic partnerships for its enabling TriGrid technology. Learn more at www.ichorms.com.
Ileo’s revolutionary nanotechnology precisely layers bile acids around peptides, proteins, vaccines or small molecules to create successful oral formulations of injectable drugs. Comprised solely of biocompatible excipients, the technology has demonstrated 25-45% bioavailab
InnoCore Pharmaceuticals is a biopharmaceutical drug delivery company specialized in the development of complex parenteral sustained release formulations. By using our proprietary biodegradable polymers we can make microspheres, erodible gels and solid implants resulting in long acting and minimally invasive drug delivery products of small, medium sized (peptides) and large (proteins, antibodies) drug molecules. Learn more at www.innocorepharma.
InnoMedica is a young swiss pharma company that provides tissue-specific liposomes for enhanced drug delivery. Employed is a novel cGMP-compliant industry-scale and cost-effective production process that generates special liposomes with unique pharmaceutical behaviors. Given the breadth of the innovation, partnering would be possible within or besides InnoMedica’s own flagship projects in oncology, neurology, and bacteriology. Learn more at www.innomedica.com.
Interface Biologics (IBI) is an early commercial stage privately held company developing innovative material science technologies for Medtech and Pharmaceutical Healthcare Products. IBI’s Endexo™ family of molecules, currently used in FDA approved vascular access products, are blended directly into medical device resins during manufacturing to create a surface resistant to blood clotting and bacterial adhesion, without the need for coatings. IBI’s has two distinct drug delivery platforms: Epidel™ (lead product a dexamethasone sustained release intravitreal implant) and Kinesyx™ (part of IBI’s proprietary Endexo™ family re-purposed as an excipient to deliver Paclitaxel and Sirolimus from angioplasty balloons). Learn more about us at www.interfacebiologics.com.
Intract Pharma Ltd is a licensing and product development company offering advanced drug delivery technologies and unique gastrointestinal (GI) models for product innovation. As a spin-out of University College London, our company is centered around more than 20 years of research from the laboratory of Prof. Abdul Basit. We specialize in oral drug delivery and offer a range of proprietary technologies to help overcome formulation challenges and enhance product performance. Complementary to these, we have developed unique GI models as strategic tools to provide expert analysis of formulation behavior under physiologically appropriate conditions. Our drug delivery technologies have been licensed across various therapeutic indications, with products at different stages of clinical development, including Phase III studies. In addition, our in-house research and development pipeline includes the preclinical evaluation of a range of products with strong scientific and commercial promise. Learn more at www.intractpharma.com.
Leon-nanodrugs GmbH (Munich) is a nanotechnology-based drug development company focused on development of novel oral and parenteral pharmaceutical formulations and innovative drug combinations. Leon’s proprietary MJR® Technology platform provides a solution to overcome one of the key issues of most marketed therapeutics, poor water solubility, a pre-requisite for drug uptake into the body. Leon-nanodrugs has established CDMO partnerships in Europe and the US to enable access to key international markets. Leon’s first own product developed based on the MJR® Technology is planned to be submitted for Marketing Authorization in 2018. Leon-nanodrugs offers access to the next generation nano formulated drugs with added patient benefits and economical values for its partners and shareholders. Learn more at www.leon-nanodrugs.com.
At Lyndra, we are working to realize a healthier world by transforming the way we take medicine. Our team is developing pills that can last a week or more, freeing patients and caregivers of the burden of daily medications.Expected benefits of our long-acting oral therapies include: better health outcomes and quality of life, reduced side effects, improved drug efficacy, slowed spread of disease, and lower health costs. Learn more at www.lyndra.com.
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company’s proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. Learn more at www.matinasbiopharma.com.
Nanexa is a Sweden-based drug delivery company that has developed a proprietary drug delivery platform called PharmaShell®. The PharmaShell® technology is based on an inorganic nanothin shell added directly on API microparticles. The platform enables development of extended release parenteral depots for subcutaneous, intramuscular or local delivery from weeks to several months. Advantages of the technology include extended release with control of initial burst release, high drug loading (80-90%), drug release independent of API solubility, and ability to deliver peptides and biologics without degradation in-situ. Learn more at www.nanexa.com.
Ocular Therapeutix, Inc (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable
Pharmaero ApS is a 50:50 joint venture between Scandinavian Health Limited (SHL) and Xellia Pharmaceuticals ApS . Pharmaero was founded in 2009. The ADI®, Pharmaero’s key product, aims at optimizing treatment and addressing patient adherence by limiting some of the barriers in inhalation therapy. Learn more at www.pharmaero.com.
Portal is a rapidly growing medical device company in the space of drug delivery that aims to replace needle and syringes with a computer-controlled system that is needle-free and easy to use. We solve two challenges associated with injectable therapies in chronic diseases: the patient experience and treatment adherence problems. Our highly innovative technology comes from MIT and is augmented by cloud-based disease management and adherence tracking system. Portal is at the clinical stage (650+ injections in human subjects to date) and has signed its first commercial partnership with Takeda pharmaceutical. Our business model is to partner with such pharma companies and structure the relationship like a typical biotech license. Our vision is a needle-free world and our mission is to transform the experience for patients on life-changing therapies. Visit www.portalinstruments.com.
QPharma AB is an established contract manufacturing and development organization (CMDO) specialized in polymer-based delivery systems. The company has long-standing experience in the field of vaginal rings and is the selected partner of several customers for the commercial manufacturing of rings marketed worldwide. Efficiency in development and manufacturing is supported by the following essential elements: QPharma is an easy to approach agile company with a flat organization structure; Employs highly qualified drug delivery experts with a unique and proven track record; Availability of advanced (co-)extrusion capabilities. Learn more about us at www.qpharma.com.
Quantex is the innovative leader in single-use disposable pump technology. We have a catalogue of single-use pumps and also provide a design and development service for custom applications. Our engineers and designers are on hand to provide design expertise throughout the development programme and assistance into volume production. Quantex & Vernay have formed a strategic partnership to bring single-use precision pumps to the flow control market. In addition to performing a business development role Vernay can support the volume manufacture of Quantex pumps. Learn more at www.quantex-arc.com and www.vernay.com.
Recro Gainesville has a long history which started with Elan Pharmaceuticals in 1981. The site later transitioned to Alkermes and then became Recro Gainesville in 2015. The site remains a small and flexible facility that focuses on early development projects through commercial manufacturing. Many of the scientific and manufacturing staff has been affiliated with this site from its initial beginnings which emphasizes the depth and breadth of drug development experience represented by the Recro site. Recro Gainesville capabilities are focused around a broad range of OSD (oral solid dose) forms which includes customizable release profiles. We can handle DEA regulated products as well. For more information, please visit: www.recrogainesville.com
Sensile Medical is a globally leading Swiss medical technology company in the field of Large Volume Injectors. In close corporation with pharma and biotech companies, we develop devices for liquid drug delivery. Our aim is, to build bridges from drugs to patients. Learn more about us at www.sensile-medical.com.
Serina Therapeutics, Inc has developed a proprietary drug delivery polymer technology based upon the water soluble polymer poly(2-oxazoline), or POZTM . We are developing a pipeline of proprietary and partnered programs applying this platform to cancer, pain, and neurological diseases. Our most advanced program is SER-214, which is in Phase I development in patients with Parkinson’s disease. SER-214 is a once-weekly subcutaneous injection that delivers a potent dopamine agonist continuously, providing continuous dopaminergic stimulation. Learn more at www.serinatherapeutics.com.
SMC Ltd provides global contract manufacturing solutions of single-use devices for the pharmaceutical, medical and diagnostics industries. SMC provides full product services from initial concept through the final packaged device; including: program management, design and development, product manufacturing, clinical manufacturing, electronics integration, and global supply chain management. Learn more at www.smcltd.com.
Sorrel Medical believes in making people healthier their way. By innovating and manufacturing wearable drug delivery devices that deliver more, Sorrel optimizes both patient experience and pharma companies’ value. Our approach at Sorrel is all about applying technology that simplifies processes for end-users and pharma partners. We partner to provide our core strengths in device R&D, regulations and manufacturing, for a true platform solution- to deliver more, your way. Learn more at www.sorrelmedical.com.
Ypsomed is the leading independent developer and manufacturer of innovative and user-friendly self-injection systems. The customisable product platforms cover autoinjectors for prefilled syringes in 1 mL and 2.25 mL formats, prefilled patch injectors, disposable pens for 3 mL and 1.5 mL cartridges, re-usable pens that include automated injection mechanisms and easy-to-use injection devices for drugs in dual-chamber cartridges. Unique click-on pen needles and infusion sets complement the broad self-injection systems product portfolio. Ypsomed provides its partners with a complete range of technical expertise and full regulatory support for the device relevant aspects of the registration process.
Ypsomed injection systems are developed and manufactured in Switzerland with strong in-house competencies covering concept and product development, tool-making, injection moulding and automated assembly. Ypsomed is ISO 13485 certified and all processes are run according to design control and cGMP guidelines with operational QA/QC experts on-site at each location. Ypsomed’s US FDA-registered manufacturing facilities are regularly inspected by both pharma customers and regulatory agencies. Devices are supplied to global markets including US, Europe, Japan, China and India. Ypsomed has more than 30 years’ experience and well-established working relationships with numerous leading pharma and biotech companies. Learn more at www.ypsomed.com.
BAUMANN – a global leading spring and stamping manufacturer with dedicated medical approach (ISO13485). We are your competent and reliable development partner in drug delivery device projects. Visit us at www.baumann-group.com.
CBSET is a not-for-profit translational research institute specializing in the evaluation of drugs, biotherapeutics, combination products, and medical devices. We provide preclinical services including in-life testing, histopathology and regulatory consulting. Our GLP-compliant facilities host a multidisciplinary team of medical, scientific and regulatory experts who actively collaborate in getting novel technologies to market. Learn more at www.cbset.org.
Drug Delivery Experts is a premier lab facility located in San Diego, California that specializes in drug product development. We have the expertise to integrate formulations that best match delivery system and device; all while maximizing commercial potential. Learn more at www.drugdeliveryexperts.com.
DS Technology is an innovative partner for bringing creative products rapidly to market. In close cooperation with clients the company creates bespoke superior solutions on the basis customer input and needs. Partners benefit from the wealth of experience in pharmaceutical processes, a multitude of manufacturing technologies and a careful selection of the most suitable materials. DS Technology focusses on the customer, its product and success. Learn more at https://d-s.technology/en.
At Haselmeier, we work in close cooperation with our pharmaceutical partners to create and deliver the safest and easiest to use injection devices for their patients. Our proven device platforms, world leading engineering and global manufacturing capabilities combined with an intense focus on patient needs provides our partners with a total product solution that helps improve patients’ lives. Visit us at www.haselmeier.com.
Intertech Engineering specializes in disciplines centered on Medical Device design and development. Intertech supports clients through all phases of product development. Disciplines include Software Development, Hardware Development, Verification & Validation (incl. 820.70 & Part 11 Validations), Requirements Management, Risk Management and Software Regulatory Issues. Services offered include Assessments, Training, Consulting and Hands-on Engineering. Learn more at www.inea.com.
Manta Product Development is an award-winning product design firm located in Boston. We provide human experience design, technology assessment, product development, and manufacturing transfer services to our clients in the drug delivery and medical device markets. Learn more at www.mantadesign.com.
NN, Inc, a diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture complex instruments, implants and assemblies on a global basis. We partner with industry leaders to bring innovation and world-class quality to design, development and production of reusable and single-use disposable medical & drug delivery devices. Learn more at www.nninc.com.
Oakwood Labs specializes in the development and aseptic manufacturing of sustained-release microsphere products, ranging in duration from weeks to one year, through the use of our patented Chroniject™ technology. Oakwood’s FDA approved cGMP aseptic facility enables partners the ability to bring products from feasibility concepts to successful commercialization. Learn more at www.oakwoodlabs.com.
Phosphorex is a provider of customized drug delivery solutions, specializing in sustained release, targeted delivery and solubility enhancement. Our service offerings include drug encapsulation in microspheres and nanoparticles, solid dispersion, micronization and nanosizing, with aseptic processing and cGMP manufacturing capabilities. We support all stages of drug development from proof of concept to clinical trials. Learn more at www.phosphorex.com.
Polysciences, Inc provides custom manufacturing and development of biodegradable materials for drug discovery & delivery, medical devices, biotechnology, electronics and analytical chemistry industries, as well as high purity optical monomers, UV absorbing materials and specialty polymer additives to the ocular lens industry. Learn more about us at www.polysciences.com.
Renishaw is applying precision engineering technology to the challenges of medical research, diagnostics and surgical procedures. Our aim is to help leading clinicians to enhance the safety and cost-effectiveness of their procedures, improving patient outcomes through accurate delivery and development of implantable devices. Our healthcare product portfolio includes medical devices, planning software and surgical robotic systems for use in procedures such as deep brain stimulation (DBS) for Parkinson’s disease, and Stereoelectroencephalography (SEEG) for the treatment of epilepsy. We also manufacture patient specific implants (PSI) for craniomaxillofacial (CMF) surgery, often required as a result of trauma or oncology therapy. Visit us at www.renishaw.com/en.
Our core competencies consist of design, development and production of mechatronic drive systems. Since 1936, our focus has been on innovation, best in class quality and service which is our key to success for worldwide OEM customers. Sonceboz is ISO 13485 certified and active in wearable drug delivery, medical devices and laboratory industry. Pharma companies looking for Large Volume Injectors for high viscosity drugs, Dual Cartridge or Auto-reconstitution Injectors will find interesting solutions in Sonceboz’s new drug Delivery Device Platform. Customized technology modules like motor-drives, electronics, pumps and needle insertion systems are available for Medical device manufacturers.
Sonceboz’s activity in medical devices is based on a long experience in automotive where top quality, reliability and cost effectiveness is key.
Learn more at www.sonceboz.com.
Founded in 1949, Stevanato Group is committed to create systems, processes and services that guarantee the integrity of parenteral medicines. It comprises two operational divisions dedicated to serve the pharmaceutical industry: Pharmaceutical Systems with Ompi specialized in glass primary packaging and Balda, focused on specialty plastics and delivery devices; Engineering Systems with Spami, Optrel, InnoScan and SVM, specialized in glass processing, inspection systems, assembly and packaging solutions. These two divisions enjoy a close, synchronous relationship, featuring daily exchanges which ensure that Stevanato Group has complete control over the entire production process. The Group also benefits from the SGLab activity that provides technical and analytical services on the potential interaction between drug and container. Learn more at www.stevanatogroup.com.
Team Consulting is a multi-award winning medical device product development consultancy based in Cambridge, UK. Our specialists in human factors, engineering and industrial design work closely with our clients to develop complex drug delivery and medtech devices from concept to launch. Learn more at www.team-consulting.com.
teamtechnik is an international market leader in innovative production technology, offering high-quality production systems and process technology for assembly and functional testing, high-performance and precision products in the automotive, medtech and solar sector. Learn more at www.teamtechnik.com.
URSATEC stands for innovative developments in preservative-free pharmaceutical, medical device and cosmetic products such as oral and nasal sprays. Safe protection against contamination by microorganisms, even after the opening of a package, is guaranteed by the dual microbiological protection of the patented dosing systems 3K® and COMFORT®. Learn more about us at www.ursatec.com/en.
West Pharmaceutical Services, Inc. is a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Working by the side of its customers from concept to patient, West creates products that promote the efficiency, reliability and safety of the world’s pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its customers from locations in North and South America, Europe, Asia and Australia. West’s 2017 net sales of $1.6 billion reflect the daily use of approximately 112 million of its components and devices, which are designed to improve the delivery of healthcare to patients around the world. Learn more at www.westpharma.com.
Ximedica is a full-service ISO 13485-certified and FDA-registered medical product development firm providing growth platforms enabling organizations to successfully deliver an efficient, risk-mitigated path to commercialization, with products that are market-ready, and thoughtfully designed with the end user in mind. Ximedica supports small pilot productions facilitating the hand-off from development stage projects to commercial manufacturing on a larger scale. Headquarters in Providence R.I. with offices in Hong Kong, Minneapolis MN, San Francisco and Silicon Valley CA. Learn more about us at www.ximedica.com.
2018 Supporting Sponsor
TTP is an independent technology company where scientists and engineers collaborate to invent, design and develop new products and technologies. With a 30-year history of invention, our multidisciplinary teams are able to deliver across the scope of a project, from research through to ideas, design, engineering and manufacture. TTP’s state-of-the-art technical facilities are part of Europe’s largest technology hub in Cambridge, UK. Here, we work across a wide spectrum of industries – including health, telecoms, industrials and consumer – to create breakthrough solutions that bring strong commercial value to clients and the benefits of technology to all. Learn more at www.ttp.com.
2018 Soapbox Sponsors
Better Sense is a high-tech startup based in Amsterdam, passionate in applying the latest technologies, such as IoT, AI and Blockchain, to smart healthcare transformation. In addition to software, we also design our own sensor devices and work with renowned electronic manufacturers in China to produce them. As a proud member of Health Valley Netherlands, we actively partner with fellow innovators, care givers, and other players in the sector, both in the Netherlands and abroad. Learn more at www.bettersense.nl.
Cam Med is applying microfluidics technologies to develop innovative, patient-friendly medical devices. Cam Med’s ultra-thin, flexible and miniature Evopump is the first truly bandage-like wearable patch pump for actively-controllable delivery of one or multiple injectable medications. Learn more at www.myevopump.com.
Cinti Medical is dedicated to the development of an injection system for drugs that require reconstitution to simplify the preparation and injection of lyophilized drugs. We use unique and creative solutions to make an intuitive and reliable drug delivery system. We strive to reduce the number of steps needed to use a device and to reduce the number of errors when a device is used. Cinti Medical focuses on providing simple solutions to drug delivery, providing high quality devices, and creating long lasting relationships with customers. Learn more at www.cintimedical.com.
Consegna reformulates FDA approved drugs and creates new, long-acting injectable (LAI) medications with improved clinical and economic benefits to address high non-adherence, solve specific drug delivery challenges, or reduce side effects. Our Computational Drug Delivery™ technology can design LAIs faster and better than legacy practice with reduced regulatory and technical risk. Learn more at www.consegnapharma.com.
Massachusetts General Hospital (MGH) is the original and largest teaching hospital of Harvard Medical School and a biomedical research facility located in the West End neighborhood of Boston, Massachusetts. MGH has long been a leader in successfully bridging innovative science with highly advanced clinical medicine. With an annual research budget of more than $786 million, MGH conducts the largest hospital-based research program in the United States — a program that spans more than 20 clinical departments and centers across the hospital. Learn more at
SiNON Therapeutics is working to increasing the ability of drugs to cross the Blood Brain Barrier (BBB). Our patented nanoparticle, the Carbon Dot, will enable pharmaceutical companies to encapsulate their drugs in a way, which dramatically improves drug-localization to the brain. This allows for a reduction in overall dose administration to the patient, leading to reduced toxicity and side effects, while improving therapeutic index. We have developed a tunable platform delivery tool that can be engineered to target specific organs. Learn more at www.sinontp.com.
Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University are developing “TUNE”, a novel formulation platform for biologic drugs and cell therapies with highly tunable control over release kinetics. The employed microfluidic process does not employ any harmful chemical or physical conditions and has encapsulation efficiencies of near 100%. Learn more at www.wyss.harvard.edu.